Archer Pharmaceuticals, Inc. "is a fully independent health care company dedicated to enhancing and extending healthy human life.", according to the website.
Based in Sarasota, Florida, Archer Pharmaceuticals wants you to inquire on how to invest in the company.
Intending on fast-tracking ARC029 and ARC031 for the treatment of Alzheimer's and dementia (and most likely Schizophrenia in the mental health pharmaceutical industry), the person to ask questions of is Geoff Birkett, former VP of marketing for AstraZeneca, the makers of Seroquel. He has also worked for Eli Lilly, the makers of Zyprexa.
Geoff Birkett of NARSAD (National Alliance for Research of Schizophrenia and Depression)
Governance
Chief Executive : Geoff Birkett, President & CEO
Compensation*: $338,461
Chair of the Board: Thomas Rabaut
Chair's Profession / Business Affiliation: Senior Advisor, The Carlyle Group
Board Size: 18
Paid Staff Size: 18
*Geoff Birkett, became President/CEO on May 21, 2007. Mr. Birkett received compensation of $338,461 for the period of May 21, 2007 - December 31, 2007. Former President Constance E. Lieber served without compensation during her term. Compensation includes annual salary and, if applicable, benefit plans, expense accounts, and other allowances.
---
Archer Pharmaceuticals
"Archer Pharmaceuticals, Inc. intends to fast track ARC029 and ARC031, while continuing to work on other therapeutic approaches. Archer Pharmaceuticals, Inc. is a fully independent health care company dedicated to enhancing and extending healthy human life. For more information or to invest in Archer Pharmaceuticals, Inc., please contact Geoff Birkett at (484) 467-1285 or visit www.ArcherPharma.com. "
Transition from AstraZeneca's Seroquel to Archer Pharmaceuticals
Seroquel Exhibit 5, pdf format:
April 2008
Exhibit 5
Kevin Geoffrey Birkett
http://74.125.95.132/search?q=cache:xYPZT_3gSi8J:www.kfd.org.tr/files/Omnibus%2520MSJ%2520Exhibit%25205.pdf+Geoff+Birkett+astrazeneca&cd=43&hl=en&ct=clnk&gl=us
IN THE UNITED STATES DISTRICT COURTMIDDLE DISTRICT OF FLORIDA
ORLANDO DIVISION
IN RE:SEROQUEL PRODUCTS LIABILTY LITIGATION
CASE NO. 6:06-md-01769-ACC-DABMDL DOCKET NO. 17 69April 24, 2008
CONFIDENTIAL Videotaped OralDeposition of KEVIN GEOFFREY BIRKETT,held in the offices of GolkowTechnologies, Inc.,
One Liberty Place,51st Floor, Philadelphia, Pennsylvaniabeginning at approximately 9:00 a.m.,before Ann V. Kaufmann, a RegisteredProfessional Reporter, CertifiedRealtime Reporter, Approved Reporter ofthe U.S. District Court, and a NotaryPublic.GOLKOW TECHNOLOGIES, INC.One Liberty Place, 51st FloorPhiladelphia, Pennsylvania 19103877.370.3377Page 1Golkow Technologies, Inc. - 1.877.370.DEPS
--------------------------------------------------------------------------------
Page 3
Confidential - Kevin Geoffrey Birkett
Page 26Page 281A. It was more based on market1terminology and it's not what I'm2experience than testing.2familiar with. There was a core set of3Q. Okay. And then as part of3messages that we were recommending the4marketing do you also get involved in4marketing companies would use if the5delivering the message?5clinical trials delivered the data to6A. We in the global function6support them. There was no global7would deliver the global strategy, which7detail aid. Detail aids are very8would lay out the key claims that we8prescriptified and used in one country.9felt were most important to the brand.9I think it's not valid to have a global10We'd also lay out the long-term plan for10detail aid.11the brand. The local messages in the11(Below-described document12U.S., China, Japan, U.K. would be done12marked Birkett Exhibit 2.)13by the local operating company.13BY MR. BLIZZARD:14Q. Okay. So you guys were14Q. I'm going to show you what15involved with the overall strategy for15I'm going to mark as Exhibit No. 2.
Page 6
Confidential - Kevin Geoffrey Birkett
Page 330
1 currently reads; but up until we decided
2 to do another study from BOLDER, we
3 always said that Seroquel in the
4 treatment of schizophrenia and mania had
5 a unique EPS tolerability profile, which
6 it did, and I believe it still does.
7 Q. That was actually the
8 cornerstone of the marketing strategy
9 for Seroquel, wasn't it?
10 A. There was actually three
11 points to the promotion.
12 Q. What were they besides
13 superior on EPS?
14 A. Unsurpassed efficacy,
15 superior EPS to all other agents and
16 similar to placebo, and negligible
17 prolactin and sexual side effects
~18 Q. Okay.19 A. -- which were unique.
20 Q. And those three claims were
21 the cornerstone of the Seroquel
22 marketing strategy; correct?
23 A. Yes.
---
My Questions
(Kevin) Geoff Birkett
1. glutamate factor and the brain?
2. how does Alzheimer's and SZ relate?
3. does archer pharma feel they are on the cutting edge of AZ treatment?
4. could the treatment carry over into mental health and SZ,comparing the drugs to Seroquel?
5.the diabetes and weight gain, insomnia, increased psychosis and withdrawals, and substance abuse from seroquel are the most profound results of seroquel use. what are your thoughts on these?
6. how do i invest in archer pharmaceuticals?
7. what is the projected growth in the next 5 years?
8. do you expect to gain a patent(s) before Seroquel goes generic?
9. do you have anything to say to the patients who have suffered diabetes, weight gain and other permanent metabolic damage as a result of using Seroquel?
10. what would you say to people who believe and trust NARSAD? who look to researchers and pharmaceutical companies for answers for bipolar and schizophrenia treatment?
11. is there one thing you want to say to the public, to gain your trust in Archer Pharmaceuticals?
----------
I look forward to your reply here or via email. Thank you.
Subscribe to:
Post Comments (Atom)
Posts
0 comments:
Post a Comment